INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview

Inmune Bio

04/08/2026 21:20

INmune Bio Inc INMB.OQ INMB.O is expected to  show no change in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026

​LSEG's mean analyst estimate for INmune Bio Inc is for a loss of 21 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for INmune Bio Inc is $7.50, about 305.4% above its last closing price of $1.85
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.25
-0.22
-0.20
Beat
9.1
Dec. 31 2026
-0.31
-0.26
-0.20
Beat
23.1
Sep. 30 2025
-0.32
-0.32
-0.24
Beat
26.2​
Jun. 30 2025
-0.37
-0.38
-1.05
Missed
-175.1
​​Mar. 31 2025
-0.47
-0.47
-0.43
Beat
8.5
Dec. 31 2024
-0.54
-0.40
Beat
25.9​
Sep. 30 2024
-0.48
-0.50
-0.60
Missed
-20.8
Jun. 30 2024
-0.63
-0.63
-0.50
Beat
20.6
This summary was machine generated August 4 at 20:20 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)